Intestinal research

Korean Association for the Study of the Intestinal Diseases (대한장연구학회)
권호 표지
DOI QR코드

DOI QR Code

Usefulness of fecal immunochemical test and fecal calprotectin for detection of active ulcerative colitis

  • Kim, Dong Ju (Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Jeoun, Yoon Mi (Department of Psychology, Hwashin Cyber University) ;
  • Lee, Dong-won (Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Koo, Ja Seol (Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Lee, Sang Woo (Department of Internal Medicine, Korea University Ansan Hospital)
  • Received : 2018.02.12
  • Accepted : 2018.06.05
  • Published : 2018.10.30
⟨ Previous Next ⟩

Abstract

Background/Aims: Ulcerative colitis undergoes periods of exacerbation and remission. Fecal calprotectin levels increase with gut inflammation and correlate with endoscopic disease activity in ulcerative colitis. Intestinal blood loss and fecal immunochemical test levels also correlate with endoscopic disease activity. This study statistically evaluated the usefulness of fecal calprotectin, fecal immunochemical test, and C-reactive protein (CRP) as markers of disease activity. Methods: A total 106 ulcerative colitis patients who underwent endoscopy and fecal calprotectin, fecal immunochemical test, and CRP testing, from March 2015 to August 2016, were retrospectively reviewed. Disease activity was assessed using a partial Mayo score and Mayo endoscopic score. The ability of fecal and serologic tests to reflect endoscopic disease severity was statistically evaluated. Results: Among 106 patients, 68 underwent endoscopy and stool study within 2 weeks. In patients with mild to severe activity, fecal immunochemical test and fecal calprotectin were superior to CRP at Mayo endoscopic score detection rate. The area under the curves of fecal immunochemical test and fecal calprotectin for the detection of Mayo endoscopic score ${\geq}1$ were 0.956 and 0.942, respectively, and were superior to that of CRP (0.756). At Mayo endoscopic score, the effects of combination of fecal immunochemical test and CRP or fecal calprotectin and CRP were found to be higher than those of the independent fecal immunochemical test or fecal calprotectin. Conclusions: Fecal immunochemical test and fecal calprotectin can effectively detect active ulcerative colitis better than remission. As these markers reflect the status of mucosal inflammation, they may reduce the requirement for invasive endoscopic examination.

Keywords

References

  1. Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27:92-95. https://doi.org/10.1136/gut.27.1.92
  2. Brophy MB, Nolan EM. Manganese and microbial pathogenesis: sequestration by the mammalian immune system and utilization by microorganisms. ACS Chem Biol 2015;10:641-651. https://doi.org/10.1021/cb500792b
  3. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-169. https://doi.org/10.1111/j.1572-0241.2007.01556.x
  4. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-2224. https://doi.org/10.1002/ibd.22917
  5. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22. https://doi.org/10.1053/gast.2000.8523
  6. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-255. https://doi.org/10.7326/0003-4819-146-4-200702200-00003
  7. Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol 2013;108:83-89. https://doi.org/10.1038/ajg.2012.315
  8. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987;317:1625-1629. https://doi.org/10.1056/NEJM198712243172603
  9. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843. https://doi.org/10.1148/radiology.148.3.6878708
  10. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845. https://doi.org/10.2307/2531595
  11. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005;100:2519-2525. https://doi.org/10.1111/j.1572-0241.2005.00231.x
  12. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces: a methodologic study. Scand J Gastroenterol 1992;27:793-798.
  13. Rose IS, Young GP, St John DJ, Deacon MC, Blake D, Henderson RW. Effect of ingestion of hemoproteins on fecal excretion of hemes and porphyrins. Clin Chem 1989;35:2290-2296.
  14. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-1201. https://doi.org/10.1053/j.gastro.2011.06.054
  15. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004;53:1813-1816. https://doi.org/10.1136/gut.2003.038505
  16. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-46. https://doi.org/10.1002/ibd.20312
  17. Kato S, Ishibashi A, Kani K, Yakabi K. Optimized management of ulcerative proctitis: when and how to use mesalazine suppository. Digestion 2018;97:59-63. https://doi.org/10.1159/000484224

Cited by

  1. Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease vol.7, pp.None, 2020, https://doi.org/10.3389/fmed.2020.00008
  2. Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches? vol.39, pp.3, 2018, https://doi.org/10.1159/000511641
  3. Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis vol.36, pp.4, 2021, https://doi.org/10.1111/jgh.15220